Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01410370 : Continuous Endostar Infusion Combined With Radiotherapy in Patients With Brain Metastases
PhasePhase 2
AgesMin: 18 Years Max: 75 Years
Eligibility
Inclusion Criteria:

- Histologically confirmed malignancy with presence of intraparenchymal brain
metastases

- Karnofsky performance status ? 40

- Measurable disease according to RECIST criteria

- Hematologic function: WBC ? 4.0×109/L, PLT ? 80×109/L, Hb ? 90g/L

- Renal function: Cr ? 2.0×ULN

- Hepatic function: BIL ? 2.0×ULN, ALT/AST ? 5.0×ULN

- Adequate cardiac function

- Life expectancy ? 3 months

Exclusion Criteria:

- Evidence of bleeding diathesis or serious infection

- Serious cardiovascular disease (congestive heart failure, uncontrollable arrhythmia,
unstable angina, myocardial infarction, serious heart valve disease, resistant
hypertension)

- Uncontrollable mental and nervous disorders

- Pregnant or lactating women
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01410370      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740